Antidepressants and related psychiatric drugs are the most important prescription drugs worldwide, accounting for a market volume of 20 billion US$ per year. This handbook provides a complete and detailed overview of all currently available psychiatric drugs, covering more than 250 different compounds. Particular features include: * the most important information on the chemistry, pharmacology and therapeutic use of a given drug * a special layout with margin notes and compound structures allowing for quick and easy access to the desired information Written by drug developers from the pharmaceutical industry, novel drugs currently under development and new methods of treatment are listed side by side with classical drugs, allowing a direct comparison of traditional and innovative therapeutic approaches.

Now in a new Fourth Edition, Psychiatry remains the leading reference on all aspects of the current practice and latest developments in psychiatry. From an international team of recognised expert editors and contributors, Psychiatry provides a truly comprehensive overview of the entire field of psychiatry in 132 chapters across two volumes. It includes two new sections, on psychosomatic medicine and collaborative care, and on emergency psychiatry, and compares Diagnostic and Statistical Manual (DSM-5) and International Classification of Diseases (ICD10) classifications for every psychiatric disorder. Psychiatry, Fourth Edition is an essential reference for psychiatrists in clinical practice and clinical research, residents in training, and for all those involved in the treatment psychiatric disorders. Includes a a companion website at www.tasmanpsychiatry.com featuring PDFs of each chapter and downloadable images

This is a spin-off from Stephen M. Stahl's new, completely revised and updated version of his much-acclaimed Prescriber's Guide, covering drugs to treat depression.

Fluoxetine, best known by the trade name Prozac®, unlike other psychotropic drugs whose effects were serendipitously stumbled upon, was the first developed for a precise mechanism of action, that is, the ability to selectively inhibit serotonin reuptake, based upon the theory that increasing the availability of serotonin would treat major depression. Once approved by the FDA in 1987, fluoxetine quickly became the most prescribed psychotropic drug worldwide and its success in improving mood disorders has triggered the development of a large number of congener molecules, commonly known as SSRIs after their purported mechanism of action. However, a quarter of a century after its development, the idea that fluoxetine asserts its positive behavioral effect through inhibition of serotonergic reuptake is not firmly established. This book reviews several preclinical and clinical reports suggesting that the pharmacological effects of fluoxetine may be mediated by means other than the regulation of serotonin, including the regulation of gene expression, modifying epigenetic mechanisms as well as modifying microRNAs. One of the most prominent mechanisms for the therapeutic relevance of fluoxetine relates to influencing neuroplasticity by enhancing neurotropic factors, including BDNF signaling and altering adult neurogenesis. The ability of fluoxetine to rapidly increase neurosteroid levels accounts for the fast anxiolytic effects of this drug. Fluoxetine action at sigma-1 receptor or modulating glutamatergic neurotransmission as well as the combination of fluoxetine with other psychotropic drugs is discussed in relation to its therapeutic effects. While fluoxetine was primarily prescribed as an antidepressant, this drug currently represents a treatment of choice for a broad spectrum of psychiatric disorders, including post-traumatic stress disorder and a range of anxiety disorders. This drug even possesses analgesic actions and is a valuable therapy for stroke. This book also highlights emerging evidence on the gender-specific effects of fluoxetine, its potential adverse features, including its addiction liability in combination with psychostimulants, and the impact of perinatal fluoxetine exposure.

Drug-Induced Liver Injury, Volume 85, the newest volume in the Advances in Pharmacology series, presents a variety of chapters from the best authors in the field. Chapters in this new release include Cell death mechanisms in DILI, Mitochondria in DILI, Primary hepatocytes and their cultures for the testing of drug-induced liver injury, MetaHeps an alternate approach to identify IDILI, Autophagy and DILI, Biomarkers and DILI, Regeneration and DILI, Drug-induced liver injury in obesity and nonalcoholic fatty liver disease, Mechanisms of Idiosyncratic Drug-Induced Liver Injury, the Evaluation and Treatment of Acetaminophen Toxicity, and much more. - Includes the authority and expertise of leading contributors in pharmacology - Presents the latest release in the Advances in Pharmacology series

The American Psychiatric Association Publishing Textbook of Psychopharmacology is an indispensable and comprehensive resource for clinicians and trainees who prescribe psychotropic medications. Updated to reflect the new DSM-5 classification, this revised Fifth Edition maintains the user-friendly structure of its predecessors while offering in-depth coverage of the latest research in pharmacological principles, classes of drugs, and psychiatric disorders. Introductory chapters provide a theoretical grounding in clinical applications, with topics ranging from neurotransmitters to brain imaging in psychopharmacology. The bulk of the book is devoted to various classes of drugs, including antidepressants, anxiolytics, antipsychotics, mood stabilizers, and other agents, with each class divided into chapters on specific drugs -- either new or revised to include the latest findings and trends. Finally, the section on psychopharmacological treatment addresses evidence-based principles of clinical care for the full spectrum of mental disorders and conditions -- from depression to chronic pain -- as well as for specific populations and circumstances -- from children and adolescents to psychiatric emergencies -- offering information on topics such as medication selection, combination and maintenance dosing regimens, monitoring and management of side effects, and strategies for optimizing treatment response. The book's beneficial features are many: The section on principles of pharmacology has been revised and reorganized to incorporate recent discoveries from the fields of neurobiology, genetics, brain imaging, and epidemiology. History and discovery, structure--activity relationships, pharmacological profiles, pharmacokinetics and disposition, mechanisms of action, indications and efficacy, side effects and toxicology, and drug--drug interactions are addressed for each agent. This consistent structure places the desired information at the clinician's fingertips and facilitates study for trainees. Coverage of drugs approved since the last edition is thorough, encompassing new antidepressants (e.g., vortioxetine), new antipsychotics (e.g., cariprazine), and agents on the clinical horizon (e.g., ketamine). More than 180 tables and graphs present critically important data in an accessible way. A work of uncommon scientific rigor and clinical utility, The American Psychiatric Association Publishing Textbook of Psychopharmacology provides state-of-the-art information on both the principles and the practice of psychopharmacological treatment of psychiatric disorders.

Print+CourseSmart